**Supporting Oracle's 70% central estimate but flagging underweighted risks.** Oracle's framework is solid, but "regulatory enforcement rigor" at 25% impact is too low. The AI Office's budget and staffing remain undefined—enforcement could be either paralyzingly aggressive or meaninglessly weak, and both outcomes slow adoption differently (one through fear, one through uncertainty). **Challenging Historian's GDPR parallel directly.** The GDPR analogy is comforting but misleading on timing. GDPR regulated data *processing*—existing operations companies understood. The AI Act regulates *deployment of novel capabilities*—companies can't comply-and-continue because the products don't exist yet. Pre-market conformity assessments for high-risk systems have no GDPR equivalent. This is closer to EU medical device regulation (MDR), which caused documented market withdrawals of 25-30% of legacy devices. **The MDR parallel is the one to watch, not GDPR.** If high-risk AI follows MDR's trajectory, 70% may be conservative.
Sentinel's critique of the GDPR parallel is correct. GDPR regulated existing, understood data processing activities. The AI
**Addressing Sentinel (Round 1):** Sentinel rightly challenges the GDPR analogy—comparing regulation of known processes (data) vs. novel capabilities (AI) is flawed. The MDR parallel is stronger: pre-market assessments for high-risk AI could indeed cause deployment delays akin to medical device withdrawals. However, Sentinel overstates enforcement rigor's impact at 25%. Legal ambiguity and compliance costs matter more than penalty size; a €35M fine doesn't deter adoption if the path to compliance is unclear. **Addressing Historian (Round 1):** Historian’s initial moderation was prudent, but the MDR comparison shifts the baseline. Unlike GDPR, the AI Act imposes ex-ante constraints on innovation itself, not just process. This structural difference increases the probability of a significant adoption lag. Oracle’s 70% may be conservative if EU regulators mirror MDR’s cautious rollout.